Drug Approval | November 24, 2023
Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
Lack of technology transfer stands out as a formidable barrier
This product will be manufactured at Lupin’s Pithampur facility in India
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
Subscribe To Our Newsletter & Stay Updated
